The third approach is to insert or inject the alpha-emitting radionuclides directly in the or near the tumour tissue, as has been tested in Phase I clinical studies with 213Bi-DOTA-substance P locally injected in gliomas by Cordier et al. [7]. The gene discussed is TAC1; the disease is neoplasm.